| Current status of nanoscale drug delivery and the future of nano-vaccine development for leishmaniasis–A review P Prasanna, P Kumar, S Kumar, VK Rajana, V Kant, SR Prasad, U Mohan, ... Biomedicine & Pharmacotherapy 141, 111920, 2021 | 44 | 2021 |
| Immune Dysfunction in Diabetes Mellitus (DM) VK Rajana | 13* | |
| Rationally designed ionic covalent organic networks (iCONs) with efficient antimicrobial activities A Hassan, C Saritha, VK Rajana, D Mandal, N Das ACS Macro Letters 12 (3), 376-381, 2023 | 7 | 2023 |
| Limitations of current chemotherapy and future of nanoformulation-based AmB delivery for visceral leishmaniasis—An updated review P Kumar, P Kumar, N Singh, S Khajuria, R Patel, VK Rajana, D Mandal, ... Frontiers in Bioengineering and Biotechnology 10, 1016925, 2022 | 5 | 2022 |
| A new Eosin Y-based ‘turnon’fluorescent sensor for ratiometric sensing of toxic mercury ion (Hg2+) offering unaided eye detection and its antibacterial activity A Chakraborty, VK Rajana, C Saritha, A Srivastava, D Mandal, N Das Journal of Hazardous Materials 470, 134207, 2024 | 1 | 2024 |
| Design, Synthesis, and Biological Studies of C-5-Substituted Diazenyl Derivatives of Uracil as Potent and Selective Antileishmanial Agents Targeting Uridine Biosynthesis … T Das, P Kumar, S Kumar, S Mal, S Kumar, VK Rajana, S Singh, ... ACS Infectious Diseases, 2024 | | 2024 |
| Yuflyma, A High Concentration and Citrate-free Adalimumab Biosimilar, Received FDA Approval for Treating Different Forms of Inflammatory Diseases VK Rajana, SM Penumaka, C Saritha, V Ravichandiran, D Mandal Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly …, 2023 | | 2023 |
| METALLIC NANOPARTICLES USED FOR ANTILEISHMANIAL DRUG DELIVERY . DDMNH Department of biotechnology-844101 Cevella Saritha, R. Vinod Kumar, P ... POTENTIAL AREAS OF RESEARCH IN THE PHARMACEUTICS, 1 (978-81-958127-4-5 …, 2023 | | 2023 |
debabrata mandalAssociate Professor at NIPER-Hajipur在 niperhajipur.ac.in 的电子邮件经过验证
